Samsung Biologics has secured its first manufacturing base in the United States by acquiring a plant from Human Genome Sciences for $280 million. The company will establish its U.S. unit, Samsung Biologics America, and retain over 500 employees at the Rockville, Maryland site. This move aims to strengthen collaboration with North American customers, enhance supply chain resilience, and provide flexible multi-site manufacturing options.
The acquisition includes a 100% stake in Human Genome Sciences, an existing plant with an annual capacity of 60,000 liters. Samsung Biologics plans to expand the site’s capacity and upgrade technology while ensuring operational continuity and stability. The deal will allow Samsung Biologics to diversify its production facilities beyond Korea and reduce reliance on tariffs.
This move marks a significant milestone for the company, enabling it to deepen collaboration with stakeholders and ensure a reliable supply of life-saving therapeutics. With this acquisition, Samsung Biologics has established its presence in the world’s largest pharmaceutical market, enhancing its ability to respond to regional changes in the supply environment.
Source: https://www.koreatimes.co.kr/business/tech-science/20251222/samsung-biologics-takes-over-bio-plant-in-maryland-from-gsk